SavedAdd your journal

Journals / MN Kardiyoloji / 2005 / Cilt: 12 - Sayı: 5

Drug-eluting stents in acute myocardial infarction

Akut miyokard infarktüsünde ilaç kaplı stentler

Namık ÖZMEN
Ergün DEMİRALP
Ejder KARDEŞOĞLU
Bekir Sıtkı CEBECİ
Pages
367–370
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we reviewed the usage of drug eluting stents in the setting of acute myocardial infaction based on the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Drug eluting stents open a new era in percutaneous coronary interventions due to prevent restenosis, reduce ischemic symptoms and prolong event-free survival.
📊
Key Findings & Data:On the other hand, in acute myocardial infarction, which is associated with thrombus, the usage of drug eluting stents is relatively limited because of the concern about acute-subacute stent thrombosis, the cost and the difficulty to provide the stents for a short period.
💡
Conclusion & Impact:In this paper, we reviewed the usage of drug eluting stents in the setting of acute myocardial infaction based on the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Stentler · Miyokard enfarktüsü · Stents

Abstract

Drug eluting stents open a new era in percutaneous coronary interventions due to prevent restenosis, reduce ischemic symptoms and prolong event-free survival. On the other hand, in acute myocardial infarction, which is associated with thrombus, the usage of drug eluting stents is relatively limited because of the concern about acute-subacute stent thrombosis, the cost and the difficulty to provide the stents for a short period. In current studies, it was shown that the usage of sirolimus eluting stents was relatively safe and the risk of acute-subacute thrombosis hasn't been different from that of bare stents. The data were considerable limited about paclitaxel eluting and preliminary results revealed that the risk of acute-subacute thrombosis was higher. In this paper, we reviewed the usage of drug eluting stents in the setting of acute myocardial infaction based on the literature.

Özet

İlaç kaplı stentler, koroner arter hastalığı, tedavisinde restenozu, iskemik semptomları azaltmaları ve olaysız sürviyi uzatmaları nedeniyle elektif perkütan girişimlerde yaygın olarak kullanılmakta ve bu anlamda koroner arter hastalıkları tedavisinde adete bir devrim yapmışlardır. Buna karşılık, akut miyokard infarktüsü gibi trombüs yükünün eşlik ettiği akut koroner patolojilerde, akut-subakut stent trombüs korkusu, zamana karşı yarışta stent temininin zorluğu ve maliyet gibi potansiyel endişelerden dolayı ilaç kaplı stent kullanımı sınırlıdır. Sirolumus kaplı stentlerin kullanımı ile ilgili çalışmalar nispeten güvenli, akut ve subakut stent trombüs olasılığının çıplak metal stentlerle karşılaştırıldığında farklı olmadığını göstermekte iken paklitaksel kaplı stentlerle ilgili veriler ise son derece sınırlı olmakla birlikte, ilk veriler akut ve subakut trombüs riskinin nispeten yüksek olduğunu göstermektedir. Bu yazımızda, akut miyokard infarktüsünde ilaç kaplı stent kullanımını literatür bilgileri eşliğinde özetlemeyi uygun bulduk.

🔖

Cite This Article

ÖZMEN, N., DEMİRALP, E., KARDEŞOĞLU, E., CEBECİ, B. S. (2005). Drug-eluting stents in acute myocardial infarction. MN Kardiyoloji, Cilt: 12 - Sayı: 5, 367–370. https://ajindex.com/articles/297563

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Stone GW, Grines CL, Cox DA, et al. Comparison of ngioplasty with stenting, with or without abciximab, in acute liyocardial infarction. N Engl J Med 2002; 346:957-66
  2. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty ith or without stent implantation for acute myocardial infarction, tent primary angioplasty in myocardial study group. N Engl J led 1999; 341:1949-56
  3. Morice MC, Serruys PW, Sousa JE, et al. A randomised Dmparison of a sirolumus-eluting stent with a standard stent for Dronary revascularisation. N Engl J Med 2002; 346:1773-80
  4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, aclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 107:221 -31
  5. Schuhlen H, Kastrati A, Dirschinger J et al. Intracoronary stenting and risk for major adverse cardiac events during the frst month. Circulation 1998; 98:104-11
  6. Hausleiter J, Kastrati A, Mehilli J et al. Predictive factors for arly cardiac events and angiographic restenosis after coronary lacement in small coronary arteries. J Am Coll Cardiol 2002; 40:882-9
  7. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus itravenouse thrombolytic therapy for acute myocardial infarction: a uantitative review of 23 randomised trials. Lancet 2003; 361:13-20
  8. Zhu MM, Feit A, Chadow H, et al. Primary stent implabtation ompared with primary balloon angioplasty for acute myocardial ıfarction: a meta-analysis of randomised clinical trails. Am J îardiol 2001; 88:297-301
  9. Haklin A, Aymong E, Cox DA, et al. Relation between late pasncy of the infarct-related artery, left ventricular function and clinical utcomes after primary percutaneous intervention for acute myoardial infarction (CADILLAC trail). Am J Cardiol 2004; 93:349-53
  10. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology; drug-eluting stents: Part I. Circulation 2003; 107:2274-9
  11. Babapulle MN, Joseph L, Belisle P, et al. A hierarchiacal bayesian meta-analysis of randomised clinical trails of drugeluting stents. Lancet 2004; 346:583-91
  12. Lemos PA, Serruys PW, Van Domburg RT, et al. Unrestricted utilization of sirolumus-eluting stents compared with conventional bare stent implantation in 'real world'. The Rapamycin-Eluting Stents Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004; 109:190-5
  13. Goy JJ, Urban P, Seydoux C, De Benedetti E, Stauffer JC. Use of sirolumus-eluting coronary stents in routine clinical practice. Catheter Cardiovasc Interv 2004